Zydus Cadila receives final approval from USFDA for Mesalamine Extended-Release Capsules

Zydus Cadila has received final approval from the USFDA to market Mesalamine Extended-Release Capsules in the strength of 0.375 g, (US RLD: Apriso). Mesalamine Extended-Release capsules are indicated for the maintenance of remission of ulcerative colitis in adults. The drug will be manufactured at the group's formulation manufacturing facility at the SEZ, Ahmedabad.

The group now has 320 approvals and has so far filed over 400 ANDAs since the commencement of the filing process in FY 2003-04.

Shares of Cadila Healthcare Ltd. was last trading in BSE at Rs. 558.6 as compared to the previous close of Rs. 544.3. The total number of shares traded during the day was 499337 in over 12895 trades.

The stock hit an intraday high of Rs. 566 and intraday low of 536.55. The net turnover during the day was Rs. 277133951.

Source : Equity Bulls

Keywords